ULB and CHU-Charleroi
" MAker Study for COVID-19 Patient follow-up in intensive Care Unit (MASC-19) Around 5-10 % of patients suffering from COVID-19 symptom aggravation require intensive care. Among them half will die. COVID-19 is often compared to sepsis however few are known about this pathology and physicians are unable to discriminate which patients will suffer from severe symptoms. For this reason, Mask-19 project, which gathers CHU-Charleroi, the Faculties of Medicine and Pharmacy (ULB) and CNRS (France), will investigate markers in sera of COVID-19 patients collected in March and April 2020. They will be compared to septic patients by metabolomics and molecular networks for a better follow up of this specific patients "
Funding: COVID-ULB
Contact: Prof. Dr Pierre Van Antwerpen Dean of the Faculty of Pharmacy RD3- Pharmacognosy, Bioanalysis, Drug Discovery and Analytical Platform of the Faculty of Pharmacy This email address is being protected from spambots. You need JavaScript enabled to view it. +3226505263 +3226505249 https://www2.ulb.ac.be/rech/chercheurs/chercheur_29271.html

Comments : Membres du groupe de recherche : Prof. MD PhD M. Piagnerelli, Physician at the ICU of Marie Curie Hospital, CHU-Charleroi-ULB -  Prof. PhD K. Zouaoui Boudjeltia, Director of the Laboratory of Experimental Medicine, CHU-Charleroi-ULB -  PhD D. Touboul, research fellow CNRS ICSN UPR2301 (France) - Prof. PhD F. Souard, Faculty of Pharmacy (ULB) - Prof. PhD C. Delporte, Analytical Platform of the Faculty of Pharmacy (ULB) - Prof. PhD P. Van Antwerpen, Analytical Platform of the Faculty of Pharmacy (ULB)